Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters

Background/aim: Adropin is a peptide-structure hormone that plays a role in preventing the development of insulin resistance, whichhas been linked to obesity and metabolic regulation. The purpose of this study is to assess serum adropin levels and their relationshipwith metabolic parameters in psoriasis vulgaris patients both with and without metabolic syndrome (MetS).Materials and methods: Fifty-three patients and 26 healthy controls were included in this study. Serum adropin levels, fasting bloodglucose, fasting serum insulin, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, total cholesterol, and triglyceridelevels of all participants were analyzed. Enzyme-linked immunosorbent assay was used to measure serum adropin levels. Results: Serum adropin levels were 2.94 ± 0.56 ng/mL in psoriatic patients without MetS, 2.49 ± 0.77 ng/mL in psoriasis patients withMetS, and 3.37 ± 0.71 ng/mL in the control group. Multivariate logistic regression analysis was used to evaluate adropin decreases inpsoriasis patients as an independent predictor of the presence of MetS. Conclusion: The serum levels of adropin in psoriasis patients were significantly lower in the presence of MetS, and this decrease wasmore prominent than in those without MetS. Adropin may be a contributing factor for metabolic disorders and the development ofMetS in psoriasis patients.

PDF

___

1. Atakan N, Doğan S. Psoriasis a systemic disease? Turk J Dermatol 2012; 6: 119-122.
2. Balta İ, Balta Ş, Demirkol S. Cardiovascular comorbidities in patients with psoriasis. Gülhane Tıp Dergisi 2014; 56: 61-63.
3. Bilir Y, Taşlıyurt T, Kutlutürk F, Şahin Ş, Öztürk B, Kalkan G, Kaya SU, Yılmaz A. Prevalence of metabolic syndrome and insulin resistance in patient with psoriasis. J Contemp Med 2014; 4: 1-5.
4. Günaydın A, Aytimur D, Özdemir F. Psoriasis and metabolic syndrome. Turkderm 2014; 48: 95-99.
5. Coban M, Tasli L, Turgut S, Özkan S, Tunç Ata M, Akin F. Association of adipokines, insulin resistance, hypertension and dyslipidemia in patients with psoriasis vulgaris. Ann Dermatol 2016; 28: 74-79.
6. Takahashi H, Iizuka H. Psoriasis and metabolic syndrome. J Dermatol 2012; 39: 212-218.
7. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, Giannetti A, Girolomoni G. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based casecontrol study. Br J Dermatol 2012; 157: 68-73.
8. Buttler AA, Tam CS, Stanhope KL, Wolfe BM, Wolfe BM, Ali MR, O’Keeffe M, St-Onge MP, Ravussing E, Havel PJ. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab 2012; 97: 3783-3791.
9. Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, Kousoulas KG, Rogers PM, Kesterson RA, Thearle M et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 2008; 8: 468-481.
10. Kumar KG, Zhang J, Rossi J, McGuinness OP, Halem HH, Kousoulas KG, Rogers PM, Kesterson RA, Thearle M, Culler MD et al. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity 2012; 20: 1394-1402.
11. Gu X, Li H, Zhu X, Gu H, Chen J, Wang L, Harding P, Xu W. Inverse correlation between plasma adropin and ET-1 levels in essential hypertension: a cross-sectional study. Medicine (Baltimore) 2015; 94: e1712.
12. Topuz M, Celik A, Aslantas T, Demir AK, Aydin S, Aydin S. Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus. J Investig Med 2013; 61: 1161-1164.
13. Heng D, Ma S, Lee JJ, Tai BC, Mak KH, Hughes K, Chew SK, Chia KS, Tan CE, Tai ES. Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis 2006; 186: 367-373.
14. Ku SH, Kwon WJ, Cho EB, Park EJ, Kim KH, Kim KJ. The association between Psoriasis Area and Severity Index and cardiovascular risk factor in Korean psoriasis patients. Ann Dermatol 2016; 28: 360-363.
15. Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, AmigoDiaz E, Testa A, Garcia-Porrua C, Martin J, Gonzalez-Gay MA. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007; 57: 287-293.
16. González-Gay MA, González-Vela C, González-Juanatey C. Psoriasis: a skin disease associated with increased cardiovascular risk. Actas Dermo-sifiliograficas 2012; 103: 595-598.
17. Karadağ AS, Yavuz B, Ertugrul DT, Akin KO, Yalcin AA, Deveci OS, Ata N, Kucukazman M, Dal K. Is psoriasis a pre-atherosclerotic disease? Increased insulin resistance and impaired endothelial function in patients with psoriasis. Int J Dermatol 2010; 49: 642-646.
18. Gozal D, Kheirandish-Gozal L, Bhattacharjee R, MoleroRamirez H, Tan HL, Bandla HP. Circulating adropin concentrations in pediatric obstructive sleep apnea: potential relevance to endothelial function. J Pediatr 2013; 163: 1122- 1126.
19. Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta M, AlOmran M, Teoh H, Verma S. Adropin is a novel regulator of endothelial function. Circulation 2010; 122: 185-192.
20. Zhao LP, Xu WT, Wang L, You T, Chan SP, Zhao X, Yang XJ. Serum adropin level in patients with stable coronary artery disease. Heart Lung Circ 2015; 24: 975-979.
21. Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, Margolis DJ, Gelfand JM. Prevalence of metabolic syndrome in patients with psoriasis: a populationbased study in the United Kingdom. J Invest Dermatol 2012; 132: 556-562.
22. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835.